3.08MMarket Cap-559P/E (TTM)
4.4800High4.2900Low14.15KVolume4.3000Open4.3000Pre Close61.95KTurnover1.98%Turnover RatioLossP/E (Static)718.03KShares15.696052wk High0.37P/B3.06MFloat Cap2.414052wk Low--Dividend TTM713.92KShs Float3210.0000Historical High--Div YieldTTM4.42%Amplitude2.4000Historical Low4.3790Avg Price1Lot Size
InMed Pharmaceuticals Stock Forum
newsfile· 5 mins ago
Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritusAnti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
InMed Pharmaceuticals (NASDAQ: INM) has announced a 1-for-20 share consolidation to regain compliance with Nasdaq's listing requirements. The consolidation will reduce outstanding shares from 14,361,550 to approximately 718,078 common shares. The post-consolidation shares are expected to begin trading on Nasdaq Capital Market on November 15, 2024. The trading symbol 'INM' will remain unchanged...
No comment yet